BiotechTube

VS-6766 + Abemaciclib + Fulvestrant

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Breast Cancer

Conditions

Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer

Trial Timeline

Feb 23, 2023 → Dec 31, 2028

NCT ID
NCT05608252

About VS-6766 + Abemaciclib + Fulvestrant

VS-6766 + Abemaciclib + Fulvestrant is a phase 1/2 stage product being developed by Eli Lilly for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05608252. Target conditions include Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Breast Cancer were approved

Approved (20) Terminated (4) Active (0)
✅arzoxifeneEli LillyApproved
✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Abemaciclib + Fulvestrant + Standard ChemotherapyEli LillyApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05608252Phase 1/2Recruiting

Competing Products

20 competing products in Breast Cancer

See all competitors
ProductCompanyStageHype Score
Intratumoral Mitazalimab + Intratumoral NivolumabAlligator Bioscience ABPhase 1
26
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35
Abemaciclib + FulvestrantEli LillyPhase 2
27
gemcitabine + vinorelbineEli LillyPhase 2
35
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
Azenosertib + Carboplatin + PembrolizumabZentalis PharmaceuticalsPhase 1/2
26
AbemaciclibEli LillyPre-clinical
26
pemetrexed + cyclophosphamide + doxorubicin + docetaxelEli LillyPhase 2
35
arzoxifeneEli LillyApproved
43
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
BBI-940 + FulvestrantBoundless BioPhase 1
26
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
47
pemetrexed + gemcitabineEli LillyPhase 2
35
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: SorafenibEli LillyPhase 2
27